Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

  • STATUS
    Recruiting
  • End date
    Dec 27, 2022
  • participants needed
    190
  • sponsor
    University of California, San Francisco
Updated on 27 January 2021

Summary

Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART) and HIV-uninfected children not on ART. All children will be malaria-uninfected at the time of enrollment.

Description

The primary goal of the study is to assess the pharmacokinetics (PK) and safety of DP in the setting of co-administration with first-line ART regimens (EFV-, LPV/r- or DTG-based ART) in children without malaria. Up to 190 children will be enrolled in one of the 5 groups: 1, HIV-infected children age 3 - 10 years on LPV/r-based ART (n=20 for signal dose DP, 30 standard 3-dose DP). 2, HIV-infected children age 3 - 10 years on EFV-based ART (n=30), 3, HIV-infected children age 11 - 17 years on DTG-based ART (n=30), 4, HIV-uninfected children age 3-10 years (standard 3-dose DP, n=20 for PK sampling after the 1st dose DP, n=30 for sampling after the 3rd dose DP), 5, HIV-uninfected children age 11-17 years (n=30 children receiving 3-dose DP).

HIV-infected participants will be enrolled from the Baylor Uganda Center of Excellence on the Mulago Hospital Complex, Kampala, Uganda. HIV-uninfected participants will be enrolled from Masafu General Hospital (MGH) complex in Busia, and other clinics in the surrounding area. DP weight-based dosing will follow World Health Organization (WHO) Treatment Guidelines for uncomplicated malaria (April 2015). All HIV-infected participants must be stabilized (i.e. no change in regimen for at least 10 days) on EFV, LPV/r, or DTG + 2 nucleoside reverse transcriptase inhibitors (NRTI). HIV-infected children on LPV/r will be enrolled in two Phases: Phase I participants (Group L1) will receive a single dose of DP to determine the magnitude (PK and safety) of the interaction before 3 doses are evaluated, Phase II participants (Group L3) will receive a 3-dose DP regimen (which consists of 3 days of a once daily DP dose). Phase I results will inform Phase II dosing, as a lower dose of DP over 3 days may be warranted. Phase II will not begin until PK and safety results from Phase I are evaluated. Participants in L1 and L3 will be encouraged to participate sequentially in Phase I and Phase II separated by a minimum 42-day washout period; however different children may be enrolled for the 2 phases. Weight-based dose of dihydroartemisinin-piperaquine (DP): 5- <8kg, 20+160mg; 8- <11kg, 30+240mg; 11- <17kg, 40+320mg; 17- <25kg, 60+480mg; 25- <36kg, 80+640mg; 36- <60kg, 120+960mg; 60-<80kg, 160+1280mg; >80kg, 200+1600mg.

Subjects will undergo an intensive PK study sampling design, which entails multiple venous blood collections in a smaller sample of individuals to accurately estimate drug exposure over time. These studies will be conducted in both HIV-infected and HIV-uninfected participants and will allow the researchers to investigate dihydroartemisinin (DHA) and piperaquine (PQ) PK exposure in the context of EFV-, LPV/r- and DTG-based ART in HIV-uninfected children. Comparisons will be based on an intensive PK design for DP area under the concentration-time curve (AUC) estimations. A sample size of 20 children/adolescents will be needed in groups L1 and C1. A sample size of 30 will be needed for each of the other arms (D3, E3, L3, C3a, and C3b). Sampling will occur up to day 42 in the 3-dose groups given the long half-life of PQ and for 14 or 28 days in the single dose groups. The generation of an AUC will permit robust comparisons so that results will inform treatment guidelines and policy.

Details
Condition HIV infection, Drug interaction, Immunodeficiency, Primary Immunodeficiency Disorders, HIV Infections, human immunodeficiency virus, hiv disease, drug interactions, drug-drug interaction
Treatment Dihydroartemisinin-piperaquine
Clinical Study IdentifierNCT04487145
SponsorUniversity of California, San Francisco
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

All participants
Agreement to come to clinic for all follow-up PK and safety evaluations
Provision of informed consent
HIV-infected participants
Residency within 30km of Mulago Hospital
Confirmed HIV infection (confirmed positive rapid HIV test or HIV RNA as per
Ugandan guidelines)
On stable EFV-, LPV/r- or DTG-based ART for at least 10 days prior to enrollment
Age 3 - 10 years if on EFV-based ART or LPV/r-based ART
Age 11 - 17 years if on DTG-based ART
HIV-uninfected participants
Residency within 30km of Masafu General Hospital
Confirmed HIV negative test (confirmed positive rapid HIV test or HIV RNA as
per Ugandan guidelines)
Age 3 - 17 years

Exclusion Criteria

History of significant comorbidities such as malignancy, active tuberculosis or
other active WHO stage 4 disease
Receipt of any medications known to affect CYP450 metabolism (except ART)
within 14 days of study enrolment (see 4.2.1)
Hemoglobin < 7.0 g/dL
Current malaria infection or recent treatment with antimalarials within 28 days of
enrolment
Asymptomatic parasitemia detected by microscopy or rapid diagnostic test (RDT)
History of side effects with DP
Prior history of cardiac disease (personal or family), baseline corrected QT intervals (QTc) >450msec, or
receipt of any cardiotoxic drugs or those known to prolong QT intervals History of
significant comorbidities such as malignancy, active tuberculosis or other WHO
stage 4 disease
Weight < 6kg
HIV-infected females on DTG-based ART and age 13-17 years who are pregnant
or of childbearing potential and do not agree to consistent and reliable
contraception
The following medications are disallowed within 3 weeks prior to receiving
study drug
Carbamazepine
Clarithromycin
Erythromycin (oral)
Ketoconazole
Phenobarbital
Phenytoin
Rifabutin
Rifampicin
Halofantrine
Any other medication known to significantly affect CYP450 metabolism
Grapefruit juice should be avoided during the study due to its potential effects on CYP3A4
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note